CC16 predicts respiratory dysfunction and eosinophilic inflammation in severe asthma

They also examined the effects of the protein on the annual decline in FEV1 and exacerbation risk using a longitudinal approach. They recruited 127 patients with severe asthma from 30 hospitals/pulmonary clinics in Hokkaido, Japan. The standard error and least-square means were calculated for Th2 biomarkers and pulmonary function tests across CC16 tertiles at baseline. They did the same for the annual decline in FEV1 and asthma exacerbation with 5 and 3 years of follow-up, respectively.

The authors reported the following findings:

· The authors found that serum CC16 was inversely associated with sputum eosinophils and blood periostin in a dose-response manner.

· In adjusted models, baseline CC16 and FEV1/forced vital capacity ratio were positively associated.

· Patients with the lowest tertile of serum CC16 levels at baseline had a −14.3 mL decline in FEV1 than those with the highest tertile over five years of follow-up.

· The authors did not find any association of CC16 with exacerbation risk.

The authors concluded, "severe asthma patients with lower circulatory CC16 have rapid FEV1 decline and enhanced eosinophilic inflammation over time."

Reference:

The study, "Association of serum CC16 levels with eosinophilic inflammation and respiratory dysfunction in severe asthma," was published in Respiratory Medicine. DOI: https://doi.org/10.1016/j.rmed.2022.107089